Human DAF on pig cells protects against human and non-human primate sera cytotoxicity mediated by exogenous or endogenous complement, as determined by flow cytometry.
Expression of human complement regulatory proteins (CRP) in pig cells through transgenesis was proposed to prevent complement activation and the ensuing rejection of pig tissues and organs following pig-to-primate transplantation. Transplantation in non-human primates of organs from transgenic pigs for human decay accelerating factor (hDAF) did not undergo hyperacute rejection, but hDAF could not prevent humoral xenograft rejection (AHXR). A possible explanation for the lack of efficacy of the expression of human complement regulatory proteins in pig cells to prevent AHXR may be interspecies differences between human and non-human complement regulatory system. We assayed the efficacy of transgenic hDAF expressed on porcine cells to inhibit the in vitro complement activity of primate sera. The individual cytotoxicity of sera from seven untreated baboons and of pools of normal human and baboon sera was assayed with endogenous and exogenous complement using a flow-cytometry complement-mediated cytotoxicity assay (FCCA) against peripheral blood lymphocytes (PBL) from hDAF and non-transgenic pigs. We also analyzed the anti-Galalpha1-3Gal (alphaGal) antibody titre of the baboon sera by ELISA and the expression of hDAF on the PBL surface by immunofluorescence. Transgenic hDAF expression was capable of protecting pig cells against injury produced by both baboon and human serum. Cellular expression of hDAF reduced cytotoxicity mediated by endogenous and exogenous complement, although the former was slightly higher. Humoral cytotoxicity was not related to a particular antibody but was inversely related to hDAF expression. The presence of hDAF protected pig cells against lysis by NHS more effectively than against NBS. These results confirm in vitro the protective role of hDAF in pig cells to heterologous complement mediated damage, but they also suggest that the extent of hDAF protection decreases, however, if cells express low levels of hDAF.
Díaz-Román
Tomás M
TM
Unidad de Investigación, C.H.U Juan Canalejo, Xubias de Arriba, 84, 15006, La Coruña, Spain.
Mañez
Rafael
R
López-Pelaez
Eduardo
E
Centeno
Alberto
A
Moscoso
Isabel
I
Pértegaz
Sonia
S
Doménech
Nieves
N
D000818:Animals; D030801:Animals, Genetically Modified; D000910:Antibodies, Heterophile / Q000276:immunology; D018958:CD55 Antigens / Q000235:genetics / Q000276:immunology*; D002478:Cells, Cultured; D003167:Complement Activation / Q000235:genetics / Q000276:immunology*; D003165:Complement System Proteins / Q000276:immunology*; D004187:Disaccharides / Q000276:immunology; D005434:Flow Cytometry; D006084:Graft Rejection / Q000235:genetics / Q000276:immunology*; D006801:Humans; D008214:Lymphocytes / Q000276:immunology; D008954:Models, Biological; D016377:Organ Transplantation; D010215:Papio; D044967:Serum / Q000276:immunology; D013552:Swine; D014183:Transplantation, Heterologous
D000910:Antibodies, Heterophile; D018958:CD55 Antigens; D004187:Disaccharides; C055075:galactosyl-(1-3)galactose; D003165:Complement System Proteins